Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Free Research Reports on AMRS, APP, LOGM and OMER Issued by the Bedford Report Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT


Print article Print article
© Marketwire 2013
2013-03-27 13:45:55 -

NEW YORK, NY -- (Marketwire) -- 03/27/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.



Amyris Inc. (NASDAQ: AMRS) shares gained 9.4 percent on volume of over 500,000 shares traded Tuesday to close at $3.26 a share. Amyris is using its proprietary synthetic biology platform to design microbes, primarily yeast, and use them as living factories in established fermentation processes to convert plant-sourced sugars into renewable hydrocarbons.





Find out more about Amyris including full access to the free equity report at: www.BedfordReport.com/AMRS : www.bedfordreport.com/AMRS



American Apparel Inc. (NYSE: APP) shares surged 12.86 percent on more than five times the average daily volume Tuesday to close at $2.37 a share. The company earlier this month reported comparable sales for February 2013 increased 6 percent, marking the 21st consecutive month of positive comparable store growth.



Find out more about American Apparel including full access to the free equity report at: www.BedfordReport.com/APP : www.bedfordreport.com/APP



LogMeIn Inc. (NASDAQ: LOGM) shares spiked 19.57 percent on volume of over 2.0 million shares traded Tuesday to close at $21.26 a share. The company on Tuesday stated that a federal jury has ruled in its favor in a patent-infringement case with 01 Communique.



Find out more about LogMeIn including full access to the free equity report at: www.BedfordReport.com/LOGM : www.bedfordreport.com/LOGM



Omeros Corporation (NASDAQ: OMER) shares declined 9.11 percent on volume of over 1.2 million shares traded Tuesday to close at $4.09 a share. The company announced positive data from the multiple-ascending-dose (MAD) portion of the Company's Phase 1 clinical trial evaluating OMS824.



Find out more about Omeros including full access to the free equity report at: www.BedfordReport.com/OMER : www.bedfordreport.com/OMER



Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.



A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.




Contact Information:

Equity News Circuit
Email Contact : www2.marketwire.com/mw/emailprcntct?id=ED54429701BC2049



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com